Brand architecture drafted.
The EmirG master brand established as a holding identity, with Research positioned as the first operating division. Market survey of UK peptide supply completed — sourcing gaps documented.
EmirG / R is the peptide research division of the EmirG master brand — a Manchester-based supplier of reference-grade compounds for academic laboratories, contract research organisations, and independent biochemical investigators across the United Kingdom.
EmirG / R was founded in 2025 after a cumulative decade of watching the peptide supply market drift from research chemistry into supplement-adjacent marketing. The brief was narrow: source compounds researchers could cite with confidence, publish the paperwork that proves it, and stop there.
The brand operates under a single directive — receipts first, claims never. We do not market these compounds for human or animal use. We do not hint, suggest, or borrow language from the wellness industry. What we publish is what the lab measured, and what the lab measured is what we ship.
The facility sits in a light-industrial unit in south Manchester — temperature-controlled storage, cold-chain handling, and a two-desk research office. Orders packed and lodged with Royal Mail or cold-chain courier within a single working day.
We chose Manchester deliberately. It keeps us close to a dense cluster of UK research universities, short shipping distances for domestic customers, and under the authority of UK law — which is where we want our supply chain audited from.
Every batch leaves the facility with an independent HPLC and mass spec report, lot-numbered and traceable. No paper, no release. ≥99% or rejected.
We do not state, imply, or insinuate dosing, therapeutic benefit, or administration. The catalog is a research reagent list, read as such.
Every vial references a specific synthesis batch, a specific assay date, and a specific analyst sign-off. The chain of custody is public on the archive.
Neutral outer packaging, no branding on exteriors. The business invoices openly under Alliance Labs Ltd, pays UK tax, and keeps nothing off-book.
No HGH or direct analogues. No Misuse of Drugs Act scheduled compounds. No relabelled white-label stock. No customer we believe is misrepresenting use.
The EmirG master brand established as a holding identity, with Research positioned as the first operating division. Market survey of UK peptide supply completed — sourcing gaps documented.
Trading entity incorporated in England & Wales. VAT registration filed. Research-use supply policy drafted and reviewed against MHRA guidance. Manchester facility leased.
Batch EG-4001 — BPC-157 · 5mg — assayed at 99.4% HPLC, mass spec confirmed, released to the public catalog alongside its independent Certificate of Analysis.
Catalog reaches 38 stocked references across six categories. 412 batches indexed in the public assay archive. Mean purity holds at 99.2%. Rejected batches: 14.
Editorial arm launched — Compound Briefs, Methodology notes, and Industry coverage published without supplement framing. Entry is science.emirg.co.uk.
EmirG / R is a trading style of Alliance Labs Ltd — a private limited company incorporated in England & Wales. All invoices, tax filings, payment processing, and customer contracts are issued under the parent entity. EmirG is the consumer-facing brand; Alliance Labs is the legal counterparty.
◆ The R suffix denotes Research — the initial operating division under the EmirG master brand. Future divisions will carry distinct suffixes and independent trading identities, each documented openly.
Batch release notices, new compound indexing, and independent lab report publications — delivered by email. No marketing noise, no retail framing.